US-based Inovalon has partnered with DoseMe to incorporate the DoseMeRx platform into its VigiLanz Pharmacy Surveillance solution, facilitating continuous safety monitoring.
This integration is anticipated to assist pharmacy teams in streamlining workflows, enhancing patient outcomes, and minimising adverse drug events resulting from dosing inaccuracies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With the integration of DoseMeRx into the VigiLanz application, customers will get immediate access to precision dosing within their surveillance processes.
This newly introduced feature identifies the effective drug regimen for every patient, facilitating smoother clinician workflows and enhancing confidence in dosing choices.
DoseMeRx utilises genotypes, drug concentrations, patient characteristics, and clinically validated Bayesian pharmacokinetic and pharmacodynamic models to determine the optimal dose in just seconds.
Inovalon provider surveillance and safety SVP Hayley Burgess said: “Hospitals face rising resistance to critical antibiotics, new regulatory pressures, and ongoing pharmacy staffing shortages, all while working with fragmented data and increasing demands to demonstrate ROI [return on investment].
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The integration of DoseMeRx with Inovalon’s VigiLanz Pharmacy Surveillance software equips pharmacy teams with near real-time insights to improve patient outcomes, maximise limited resources, and support greater compliance across the healthcare system.”
The integrated solution facilitates easy adoption, requiring minimal time for training and implementation, and integrates into existing clinical workflows without necessitating additional data entry.
DoseMeRx optimises non-time-critical dosing for immunosuppressants, oncology agents, antimicrobials, and other medications, thereby minimising drug-related risks.
Furthermore, it enhances therapeutic drug monitoring and incorporates precision dosing into clinical surveillance directly.
DoseMe chief commercial officer John Hardesky said: “Hospitals everywhere are under pressure to do more with less, and precision dosing is proving essential to improving safety, outcomes, and efficiency.
“Together with Inovalon, we’re delivering a comprehensive solution that pairs intelligent precision dosing with continuous safety surveillance to help teams act sooner and more confidently.”
